Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketorolac + bromfenac
- Development stage
- Unknown
- Lead developer
- Bausch + Lomb
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Ketorolac + bromfenac is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs) used primarily in ophthalmology to manage pain and inflammation, especially following eye surgeries such as cataract extraction or refractive procedures. Both agents act by inhibiting cyclooxygenase enzymes (COX), thereby blocking prostaglandin synthesis, which mediates inflammation and pain. Ketorolac is a non-selective COX inhibitor with activity against both COX-1 and COX-2, while bromfenac shows greater selectivity for COX-2. This combination may offer enhanced analgesic efficacy and anti-inflammatory effects compared to monotherapy, with studies suggesting that both are effective for postoperative ocular pain control[3][4][5][6][8]. The drugs are typically administered topically as ophthalmic solutions.
- Brand names
- XibromProlensa
- Other names
- ketorolac tromethaminebromfenac sodium
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on ketorolac + bromfenac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketorolac + bromfenac.